Galectin-3 Is a Potential Mediator for Atherosclerosis

Table 2

Classical Gal-3 modulators in the present relative studies.

Modulator	Subtype	Function	Targets	Mechanism	Authors
MCP	—	Inhibition	Leukocytes and endothelial cells	Inhibition of the adhesion between leucocytes and endothelial cells	Lu et al. [90]
			ApoE^-/- mice	—	MacKinnon et al. [52]
			Heart failure mice	Reducing myocardial inflammation and fibrogenesis	Vergaro et al. [91]
Statin	Pravastatin	Inhibition	Acute coronary syndrome patients	—	Cannon et al. [94]
	Rosuvastatin		Heart failure patients		Gullestad et al. [80]
	Atorvastatin		ApoE^-/- mice		Lee et al. [46]
Quinapril	—	Inhibition	Diabetic RAGE^-/-/gal-3^-/- mice	Reducing macrophage infiltration and vascular collagen deposition	Watson et al. [58]
MRAs	—	Inhibition	Myocardial infarction mice	Attenuation of cardiac fibrosis, left ventricular dysfunction, and heart failure	Lax et al. [95]
LacNac	—	Inhibition	Gal-3^-/- mice		Yu et al. [57]
Aldosterone	—	Activation	Macrophages	—	Lin et al. [96]
Doxazosin	—	Activation	Cardiomyocytes	—	Qian et al. [97]

Abbreviations: Gal-3: galectin-3; MCP: modified citrus pectin; MRAs: mineralocorticoid receptor antagonists; LacNac: N-acetyllactosamine.